Novartis building Chinese presence with vaccines acquisition and R&D investment
This article was originally published in Scrip
Novartis has become the latest multinational to set its sights on the fast-growing vaccines market in China, where it has unveiled plans to acquire a Chinese manufacturer, and is also investing $1 billion over the next five years to build up its R&D operations in the country.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.